Amgen (AMGN) director acquires 218.6134 shares; holds 4,958.6425
Amgen (AMGN) reported a director transaction.
Rhea-AI Filing Summary
Amgen (AMGN) reported a director transaction. On 11/07/2025, the reporting person acquired 218.6134 shares of common stock at $0, reflecting equity credited under the company’s director program.
Following this activity, the director beneficially owned 4,958.6425 shares, held directly. The filing notes these shares include 268 Dividend Equivalents credited on vested but deferred RSUs, which are paid out in shares on a one-to-one basis with cash for any remaining fractional amount.
Positive
- None.
Negative
- None.
Insights
Routine director equity accrual; no open-market purchase.
This Form 4 shows a director received 218.6134 common shares at $0, consistent with equity credited under a director program rather than a market transaction. Such entries often reflect dividend equivalents or deferred share units vesting.
The position now totals 4,958.6425 shares, held directly. The note specifies 268 Dividend Equivalents tied to vested but deferred RSUs, paid in shares one-for-one plus cash for any fractional remainder. No cash flow to the issuer or open-market signal is indicated in the excerpt.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 218.6134 | $0.00 | $0.00 |
Footnotes (1)
- F1. These shares include 268 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
AI-generated analysis. How Rhea-AI works. Not financial advice.